A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DCDT2980S in Combination With Rituximab or DCDS4501A in Combination With Rituximab in Patients With Relapsed or Refractory B-cell Non Hodgkin's Lymphoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Safety: Incidence of adverse events
Up to approximately 1 year
No
Clinical Trials
Study Director
Genentech
United States: Food and Drug Administration
GO27834
NCT01691898
September 2012
December 2014
Name | Location |
---|---|
Fountain Valley, California 92708 | |
Miami, Florida 33176 | |
Albany, New York 12208 | |
Cleveland, Ohio 44195 | |
Nashville, Tennessee 37203-1632 | |
Austin, Texas 78705 | |
Seattle, Washington 98195 | |
Flint, Michigan 48532 | |
McLean, Virginia 22101 | |
Hackensack, New Jersey 07601 | |
Denver, Colorado | |
Boston, Massachusetts | |
Eugene, Oregon | |
Milwaukee, Wisconsin | |
Washington, District of Columbia | |
Las Vegas, Nevada 89109 |